FDA Review Divisions: Performance Levels and the Impact on Drug Sponsors

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|91|3|393-404

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.91, Iss.3, 2012-03, pp. : 393-404

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 1, 2015-01 ,pp. : 29-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent

By  

Cardiology, Vol. 120, Iss. 3, 2012-01 ,pp. : 169-171

Karger

Access to resources Recommend Favorite

Sponsors

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. S2, 2015-03 ,pp. : v-v

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA approves new drug to treat schizophrenia, MDD

By  

MENTAL HEALTH WEEKLY, Vol. 25, Iss. 28, 2015-07 ,pp. : 6-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

The FDA Prasugrel Review: Adjudication of Myocardial Infarction Controversy

By  

Cardiology, Vol. 114, Iss. 2, 2009-06 ,pp. : 126-129

Karger

Access to resources Recommend Favorite